BIBLIOGRAPHIE : Thérapies Psychédéliques.

Docteur Christian SUEUR, GRECC, version actualisée, décembre 2020.

Addictions et thérapies psychédéliques : pp 23 – 29

Cf également **Bibliographie : Microdosing psychédéliques**, Dr C. Sueur, GRECC, février 2020.)

1. AARONSON B., OSMOND H. (Eds.) : Psychedelics : The uses and implications of hallucinogenic drugs, Garden City, NY, Anchor Books.
2. AARONSON B.S., OSMOND H. : Introduction, in « *Psychedelics : The Uses and Implications of Hallucinogenic Drugs* », ed. by Aaronson B.S. and Osmond H., New York, Anchor Books, 1970, 3-20.
3. ABRAMSON H.A. : Lysergic Acid Diethylamide (LSD-25) : XIX. As an adjunct to brief psychotherapy, with special reference to ego enhancement, *Journal of Psychology*, 1956, 41, 199.
4. ABRAMSON H.A. (Ed.) : Use of LSD in Psychotherapy and Alcoholism, Bobbs-Merrill, Indianapolis, 1967, 407-426.
5. ABRAMSON H.A. : Comparison of LSD with methysergide and psilocybin on test subjects, in : Abramson HA (ed) « *The Use of LSD in Psychotherapy and Alcoholism* », Bobbs-Merrill Company Inc., Indianapolis, 1967.
6. ADAY J.S., BLOESCH E.K., DAVOLI C.C. Beyond LSD : A Broeder Psychedelic Zeitgeist during the Early to Mid-20th Century, *Journal of Psychoactive Drugs*, 2019, 1-8. Doi : 10.1080/02791072.2019.1581961
7. AKERS J. : The psychedelic renaissance : Ethnopharmacology, neuroscience and clinical efficacity, *Australasian Anesthesia*, 2019, 203-217.
8. ALNAES R. : Therapeutic application of the change in consciousness produced by psycholytica (LSD, Psilocybin, etc.), *Acta Psychiatrica Scandinavica*, 1964, 39, (S180), 397–409.
9. ALONSO J.F., ROMERO S., MANANAS M.A. et al. : Serotonergic psychedelics temporarily modify information transfer inhumans, *International Journal of Neuropsycho-pharmacology*, 2015, 18, pyv039.
10. ANDERSON B.T. : Ayahuasca as Antidepressant ? Psychedelics and Styles of Reasoning in Psychiatry, *Anthropology of Consciousness,* 2012, vol. 23, no. 1, 44-59.
11. ANDERSON B.T., LABATE B.C., MEYER M., TUPPER K.W., BARBOSA P.C., GROB C.S. et al. : Statement on ayahuasca, *International Journal of Drug Policy*, 2012, 23, 173–175.
12. ANDERSON T., PETRANKER R., DINH-WILLIAMS L., ROSENBAUM D., WEISSMAN C., HAPKE E., FARB N. : Microdosing Psychedelics : Personality, Mental Health, and Creativity Differences in Microdosers, version preprint, 6 november 2018.
13. ANDERSON T., PETRANKER R. : Opening up the future of psychedelic science, The Conversation, 2018, 4 p.

14. ANDERSON T., PETRANKER R., CHRISTOPHER A., ROSENBAUM D., WEISSMAN C., DINH-WILLIAMS L.-A. , HUI K., HAPKE E. : Psychedelic microdosing benefits and challenges : an empirical codebook, *Harm Reduction Journal*, 2019.
Doi : 10.1186/s12954-019-0308-4
15. ANDERSON T., PETRANKER R., CHRISTOPHER A., ROSENBAUM D., WEISSMAN C., DINH-WILLIAMS L.-A. , HUI K., HAPKE E. : Psychedelic microdosing benefits and challenges : an empirical codebook, *Harm Reduction Journal*, 2019.
Doi : 10.1186/s12954-019-0308-4
16. APUD I. : Pharmacology of Consciousness or Pharmacology of Spirituality ? A Historical Review of Psychedelic Clinical Studies, *The Journal of Transpersonal Psychology*, 2016, 48, (2), 150-167.
17. ARGENTO E., TUPPER K.W., SOCIAS M.E. : The tripping point : The potential role of psychedelic-assisted therapy in the response to the opioid crisis, *International Journal of Drug Policy,* 2019, 2 pp.
Doi : 10.1016/j.drugpo.2018.11.006
18. ARGENTO E., CAPLER R., THOMAS G., LUCAS P., TUPPER K.W. : Exploring ayahuasca-assisted therapy for addiction : A qualitative analysis of preliminary findings among an Indigenous community in Canada, *Drug and Alcohol Reviews*, 2019, 1-9.
Doi : 10.1111/dar.12985
19. BAHI C. : Psilocybin based therapy for cancer related distress, a systematic review and meta-analysis, Thèse de Pharmacie, Université de Franche Comté, 2018, 33 p.
20. BAKALAR J. : Psychedelic drug therapy : Cultural conditions and obstacles, *Journal of Altered States of Consciousness*, 1979, 5, (4), 297-307.
21. BAKALAR J., GRINSPOON L. : Can drugs be used to enhance the psychotherapeutic process? *American J. of Psychotherapy*, 1986, XL, (3), 1986.
22. BARKER S.A. : N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen : Past, Present, and Future Research to Determine its Role and Function, *Frontiers in Neuroscience*, 2018, 12, Article 536, 1-15.
Doi : 10.3389/fnins.2018.00536
23. BARRETT F.S., BRADSTREET M.P., LEOUTSAKOS J.M.S., JOHNSON M.W., GRIFFITHS R.R. : The challenging experience questionnaire : Characterization of challenging experiences with psilocybin mushrooms, *Journal of Psychopharmacology*, 2016, 30, (12), 1279–1295.
24. BARRETT F.S., JOHNSON M.W., GRIFFITHS R.R. : Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin, *Journal of Psychopharmacology,* 2015, 29, (11), 1182–1190.
Doi : 10.1177/0269881115609019
25. BARRETT F.S., JOHNSON M.W., GRIFFITHS R.R. : Neuroticism is associated with challenging experiences with psilocybin mushrooms, *Personality and Individual Differences*, 2017, 117, 155–160.
26. BARRETT F.S., ROBBINS H., SMOOKE D., BROWN J.L., GRIFFITHS R.R. : Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions, *Frontiers in Psychology*, 2017, 8, 1238.
27. BARRETT F.S., PRELLER K.H., KAELEN M. : Psychedelics and music : neuroscience and therapeutic implications, *International Review of Psychiatry*, 2018, 1-13.
Doi : 10.1080/09540261.2018.1484342
28. BASTIAANS J. : Mental Liberation Facilitated by the Use of Hallucinogenic Drugs, in « *Psychedelic Reflections* », ed. by Grinspoon L. and Bakalar J.B., New York, Human Sciences, 1983, 143-152.

29. BAUMEISTER D., BARNES G., GIAROLI G., TRACY D. : Classical hallucinogens as antidepressants ? A review of pharmacodynamics and putative clinical roles, *Therapeutic Advances in Psychopharmacology*, 2014, 4, 156-169.
30. BEGOLA M.J., SCHILLERSTROM J.E. : Hallucinogens and Their Therapeutic Use : A Literature Review, *Journal of Psychiatric Practice*, 2019, 25, (5), 334–346. Doi : 10.1097/PRA.0000000000000409
31. BEDI G. : 3,4-Methylenedioxymethamphetamine as a psychiatric treatment, *JAMA Psychiatry*, 2018, 21. Doi : 10.1001/jamapsychiatry.2018.0063
32. BENKO J., VRANKOVA S. : Natural Psychoplastogens as Antidepressant Agents, *Molecules*, 2020, 25, (5), 1172. Doi : 10.3390/molecules25051172
33. BENSOUSSAN P., JOANNIDÈS A.A. : A propos de l'expérience psychédélique, *Annales Médico-Psychologiques*, 1967, I, (1), p 116.
34. BERINGER K. : Der Meskalinrausch seine Geschichte und Ercheinungsweise, Berlin, Springer Verlag, 1927.
35. BIANCARDI V. : La recherche sur les microdoses de substances psychédéliques. James Fadiman, Sophie Forbes et les « micro-doses », *Revue Chimères*, 2017, 1, 91, 139-148. https://www.cairn.info/revue-chimeres-2017-1-page-139.htm
36. BIANCARDI V. : Le microdosage de substances psychédéliques : bref historique et nouveaux axes de recherche, *Revue Circé*, 2019, 11, 1-24. http://www.revue-circe.uvsq.fr/biancardi-microdosage-de-substances-psychedeliques/
37. BICKERDIKE M.J. : 5-HT2C receptor agonists as potential drugs for the treatment of obesity, *Current Topics in Medicinal Chemistry*, 2003, 3, (8), 885-897. PMID: 12678838
38. BOIRE R.G. : Psychedelic Medicine and the Law, , in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 1)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, London, 2007, 217-232.
39. BRAVO G., GROB C.S. : Psychedelics and transpersonal psychiatry, in B.W. Scotton, A.B. Chinen & J.R. Battista (Eds.) "*Textbook of transpersonal psychiatry and psychology",* New York, Basic Book, 1996, pp 176-183.
40. BRIGLIO J., Therapeutic Potential of Psychedelic Drugs, University of Maine, USA, 1-32.
41. BUSCH A.K., JOHNSON W.C. : LSD 25 as an aid in psychotherapy; preliminary report of a new drug, *Diseases of the Nervous System,* 1950, 11, (8), 241–243.
42. CALABRESE J.D. : The Therapeutic Use of Peyote in the Native American Church, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 2)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, 2007, 29-42.
43. CALDERON S.N., HUNT J., KLEIN M. : A regulatory perspective on the evaluation of hallucinogen drugs for human use, *Neuropharmacology*, 2018, 142, 135-142. Doi : 10.1016/j.neuropharm.2017.11.028
44. CAMERON A., LUKE D., WALDSTEIN A., SESSA B., KING D. : Breaking Convention. Essays on Psychedelic Consciousness, North Atlantic Books, Berkeley, CA, 2013, 2014.
45. CALDWELL W.V. : LSD Psychotherapy : An Exploration of Psychedelic and Psycholytic Therapy, New York, Grove, 1967.

46. CARHART-HARRIS R.L., NUTT D. : Users perceptions of the benefits and harms of hallucinogenic drug use : A web-based questionnaire study, *Journal of Substance Use*, 2010, 15, 283-300.
47. CARHART-HARRIS R.L., LEECH R., WILLIAMS T., ERRITZOE D., ABBASI N., BARGIOTAS T. et al. : Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin, *British Journal of Psychiatry*, 2012, 200, 238–244.
Doi : 10.1192/bjp.bp.111.103309
48. CARHART-HARRIS R.L., BOLSTRIDGE M., RUCKER J., DAY C.M.J., ERRITZOE D., KAELEN M., BLOOMFIELD M., RICKARD J.A., FORBES B., FEILDING A., TAYLOR D., PILLING S., CURRAN V.H., NUTT D.J. : Psilocybin with psychological support for treatment-resistant depression : an open-label feasibility study, *Lancet Psychiatry*, 2016, 3, (7), 619–627.
Doi : 10.1016/S2215-0366(16)30065-7
49. CARHART-HARRIS R.L., ROSEMAN L., BOLSTRIDGE M., DEMETRIOU L.J., PANNEKOEK N., WALL M.B., TANNER M., KAELEN M., McGONIGLE J., MURPHY K., LEECH R.H., CURRAN V., NUTT D.J. : Psilocybin for treatment-resistant depression : fMRI-measured brain mechanisms, *Scientific Reports*, 2017, volume 7, Article 13187.
50. CARHART-HARRIS R.L., GOODWIN G.M. : The Therapeutic Potential of Psychedelic Drugs : Past, Present and future, *Neuropsychopharmacology*, 2017, 42, 2105-2113.
Doi : 10.1038/npp.2017.84
51. CARHART-HARRIS R.L., BOLSTRIDGE M., DAY C.M.J., RUCKER J., WATTS R., ERRITZOE D., KAELEN M., GIRIBALDI B., BLOOMFIELD M., PILLING S., RICKARD J.A., FORBES B., FEILDING A., TAYLOR D., CURRAN H.V., NUTT D.J. : Psilocybin with psychological support for treatment-resistant depression : six-month follow-up, *Psychopharmacology*, 2018, 235, 399-408.
Doi : 10.1007/s00213-017-4771-x
52. CARHART-HARRIS R.L. : Upcoming trial - Psilocybin for major depression: A randomised control trial, Imperial College of Science, 2018, https://www.imperial.ac.uk/department-of-medicine/research/brainsciences/psychiatry/psychedelics/
53. CARHART-HARRIS R.L., ROSEMAN L., HAIJEN E. et al. : Psychedelics and the essential importance of context, *Journal of Psychopharmacology,* 2018, 32, (7), 725–731.
54. CARTER O.L., PETTIGREW J.D., BURR D.C., ALAIS D., HASLER F., VOLLENWEIDER F.X. : Psilocybin impairs high-level but not low-level motion perception, *NeuroReport*, 2004, 15, 12, 1947-1951.
55. CARTER O.L., BURR D.C., PETTIGREW J.D., WALLIS G.M., HASLER F., VOLLENWEIDER F.X. : Using Psilocybin to Investigate the Relationship between Attention, Working Memory, and the Serotonin 1A and 2A Receptors, *Journal of Cognitive Neuroscience*, 2005, 17, 10, 1497-1508.
56. CARTER O.L., PETTIGREW J.D., HASLER F., WALLIS G.M., LIU G.B., HELL D., VOLLENWEIDER F.X. : Modulating the Race and Rythmicity of Perceptual Rivalry Alternations with the Mixed 5-HT2A, 5-HT1A Agonist Psilocybin, *Neuropsychopharmacology*, 2005, 30, 1154-1162.
57. CARTER O.L., HASLER F., PETTIGREW J.D., WALLIS G.M., LIU G.B., VOLLENWEIDER F.X. : Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans, *Psychopharmacology*, 2007, 195, 415-424.
Doi : 10.1007/s00213-007-0930-9

58. CAVALCANTE e COSTA G.P., NISHIJO H., FERREIRA CAIXETA L.F., AVERSI-FERREIRA T.A. : The Confrontation between Ethnopharmacology and Pharmacological Tests of Medicinal Plants Associated with Mental and Neurological Disorders, *Hindawi - Evidence-Based Complementary and Alternative Medicine*, 2018, Article ID 7686913, 27 pages.
Doi : 10.1155/2018/7686913
59. CHAMBON O. : La médecine psychédélique, Ed. Les Arènes, Saint-Amand-Montrond, 2009, 396 p.
60. CINI F.A., ORNELAS I., MARCOS E., GOTO-SILVA L., NASCIMENTO J., RUSCHI S., SALERNO J., KARMIRIAN K., COSTA M., SEQUERRA E., de ARAUJO D., TOFOLI L.F., RENNO-COSTA C., MARTINS-de-SOUZA D., FEILDING A., REHEN S., RIBEIRO S. : D-lysergique acid diethylamide has major potential as a cognitive enhancer, *BioRxiv*, 2019.
Doi : 10.1101/866814
61. CLARIDGE G. : LSD a missed opportunity ?, *Human Psychopharmacology*, 1994, 9, 343-351.
62. COLE J.O., KATZ M.M. : The psychotomimetic drugs : an overview, *JAMA*, 1964, 187, (10), 758–765.
http://druglibrary.net/schaffer/lsd/colekatz.htm
63. COLEMAN R. : Psychedelic Psychotherapy. A User Friendly Guide to Psychedelic Drug Assisted Psychotherapy, Transform Press, Berkeley, CA, USA, 2018.
64. CROCKET R., SANDISON R.A., WALK A. (eds) : Hallucinogenic Drugs and their Therapeutic Use, *Proceedings of the Quarterly Meeting of the Royal Medico-Psychological Association in London 1961*, London: H. K. Lewis, 1963.
65. DANFORTH A.L., LUKOFF D., FADIMAN J. : *Course* : Psychedelics : Theory, Research & Clinical Applications, *The Institute of Transpersonal Psychology*, Palo Alto, CA, USA, 2011.
66. DANFORTH A.L., GROB C.S., STRUBLE C., FEDUCCIA A.A., WALKER N., JEROME L., YAZAR-KLOSINSKI B., EMERSON A. : Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults : a randomized, double-blind, placebo-controlled pilot study, *Psychopharmacology*, 2018, 235, 3137-3148.
Doi : 10.1007/s00213-018-5010-9.
67. DAVIS A.K., LANCELOTTA R., BARSUGLIA J.P., GRIFFITHS R.R. : 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvments in depression and anxiety, *The American Journal of Drug and Alcohol Abuse,* 2019, 45, (2), 161-169.
Doi : 10.1080/00952990.2018.1545024
68. DENBER H.C. : Mescaline and Lysergic Acid Diethylamide : Therapeutic Implications of the Drug-Induced State, *Diseases of the Nervous System*, 1969, 30, suppl (2), 23-27.
69. DENSON R. : Complications of Therapy with Lysergide, *Canadian Medical Association Journal*, 1969, 101, (11), 53-57
70. De FAZIO C. : Drogues psychédéliques : un traitement contre la dépression ? *Sciences et Avenir*, 2018 19 juin, 1-3
71. De GREGORIO D., ENNS J.P., NUNEZ N.A., POSA L., GOBBI G. : D-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens : Mechanism of action and potential therapeutic applications in mood disorders, Chapter 3, *Progress in Brain Research,* 2018, 242, 69-96.
Doi : 10.1016/bs.pbr.2018.07.008

72. De GREGORIO D., AGUILAR-VALLES A., PRELLER K.H., HEIFETS B.D., HIBICKE M., MITCHELL J., GOBBI G. : Hallucinogens in Mental Health : Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine, *The Journal of Neuroscience*, 2020, 1-10.
Doi : 10.1523/JNEUROSCI.1659-20.2020
73. Di LEO F. : Protocol : LSD-assisted psychotherapy correlation of peak experience profiles with behavior change, Appendix C : Peak experience profile, Unpublished, 1982.
74. DOBLIN R. : Pahnke's « Good Friday experiment » A long-term follow-up and methodological critique, *The Journal of Transpersonal Psychology*, 1991, 23, (1), 1-28.
75. Dos SANTOS R.G., OSORIOS F.L., CRIPPA J.A.S., RIBA J., ZUARDI A.W., HALLAK J.E.C. : Antidepressive, anxiolytic, and anti-addictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years, *Therapeutic Advances Psychopharmacology*, 2016, 6, 3, 193– 213.
Doi : 10.1177/2045125316638008
76. Dos SANTOS R.G., BOUSO J.C., HALLAK J.E.C. : Serotoninergic hallucinogens/ psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer, *BMC Psychiatry,* 2019, 19, 321, 1-4.
Doi : 10.1186/s12888-019-2288-z
77. Dos SANTOS R.G., HALLAK J.E.C. : Therapeutic use of serotoninergic hallucinogens : A review of the evidence and of the biological and psychological mechanisms, *Neuroscience and Biobehavioral Reviews*, 2020, 108, 423-434.
Doi : 10.1016/j.neubiorev.2019.12.001
78. DYCK E. : Psychedelic Psychiatry. LSD, from clinic to campus, The John Hopkins University Press, Baltimore, 2008.
79. EDEL Y. : Expérimentations des psychodysleptiques à Sainte-Anne dans les années 1960, *Annales Médico-Psychologiques*, 2017, 175, 653-660.
Doi : 10.1016/j.amp.2017.08.003
80. EISNER B., COHEN S. : Psychotherapy with lysergic acid diethylamide, *Journal of Nervous and Mental Disease*, 1958, 127, (6), 528-539.
81. EISNER B.G. : remembrances of LSD therapy past, Manuscript Book, Santa Monica, CA, 2002, 200 p.
82. ELSEY J.W.B. : Psychedelic drug use in healthy individuals : A review of benefits, costs, and implications for drug policy, *Drug, Science, Policy and Law,* 2017, 3, 1-11.
Doi : 10.1177/2050324517723232
83. ERRITZOE D., RICHARDS W.A. : Lessons to be learned from early psychedelic therapy in Denmark, *Nordic Journal of Psychiatry*, 2017, 71, (7), 487–488.
84. FADIMAN J. : Microdose research without approvals, control groups, double-blinds, staff or funding, note non publiée, 2010.
85. FADIMAN J. : The Psychedelic Explorer's Guide, in « *Psychedelic Medicine* », R.L. Miller Ed., Rochester, Vermont, Park Street Press, 2011.
86. FAILLACE LA : Clinical use of psychotomimetic drugs, *Comprehensive Psychiatry*, 1966, 7, (1), 13–20.
87. FOLDI C.J., LIKNAITZKY P., WILLIAMS M., OLDFIELD B.J. : Rethinking Therapeutic Strategies for Anorexia nervosa : Insights From Psychedelic Medicine and Animal Models, *Frontiers in Neuroscience*, 2020, Vol 14, Article 43, 1-8.
Doi : 10.3389/fnins.2020.00043
88. FRECSKA E. : Therapeutic Guidelines : Dangers and Contraindications in Therapeutic Applications of Hallucinogens (Chapter 4), , in "*Psychedelic Medicine :*

New Evidence for Hallucinogenic Substances As Treatments (Vol 1)", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, 2007, 69-96.
89. FRECSKA E., BOKOR P., WINKELMAN M. : The Therapeutic Potentials of Ayahuasca : Possible Effects against Various Diseases of Civilization*, Frontiers in Pharmacology,* 20167, article 35.
Doi : 10.3389/fphar.2016.00035
90. FREDERKING W., Intoxicant drugs (mescaline and lysergic acid diethylamide) in psychotherapy, *Journal of Nervous and Mental Disease*, 1955, 121, 262-266.
91. FRIEDMAN H. : The Renewal of Psychedelic Research : Implications for Humanistic and Transpersonal Psychology, *The Humanistic Psychologist*, 2006, 34, (1), 39–58.
92. FUENTES J.J., FONSECA F., ELICES M., FARRE M., TORRENS M. : Therapeutic Use of LSD in Psychiatry : A Systematic Review of Randomized-Controlled Clinical Trials, *Frontiers in Psychiatry*, 2020, Vol 10, Article 943.
Doi : 10.3389/fpsyt.2019.00943
93. GARCIA-ROMEU A., KERSGAARD B., ADDY P.H. : Clinical applications of hallucinogens : A review, *Experimental and Clinical Psychopharmacology*, 2016, 24 (4), 229-268.
94. GARCIA-ROMEU A., BARRETT F.S., JOHNSON M.W., GRIFFITHS R.R. : Developing psilocybin as a potential pharmacotherapy : Identifying optimal dosing parameters, Poster presented at the *College on Problems of Drug Dependence Annual Meeting in Montreal,* Canada, 2017, June.
Doi : 10.1037/pha0000084
95. GARCIA-ROMEU A., WILLIAMS A.R. : Current perspectives on psychedelic therapy : use of serotoninergic hallucinogens in clinical interventions, *International Review of Psychiatry*, 2018, 1-26.
Doi : 10.1080/09540261.2018.1486289
96. GARCIA-ROMEU A., DAVIS A.K., EROWID E., EROWID F., GRIFFITHS R.R., JOHNSON M.W. : Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic psychedelic Use : An Online Survey, *Frontiers in Psychiatry*, 2020, Vol 10, Article 955.
Doi : 10.3389/fpsyt.2019.00955
97. GARDNER J., CARTER A., O'BRIEN K., SEEAR K. : Psychedelic-assisted therapies. The past, and the need to move forward responsibly, *International Journal of Drug Policy*, 2019.
98. GASSER P., HOLSTEIN D., MICHEL Y., DOBLIN R., YAZAR-KLOSINSKI B, PASSIE T. et al. : Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases, *Journal of Nervous and Mental Disease*, 2014, 202, 513-520.
99. GEERT-JORGENSEN et al. : LSD treatment : Experience gained within a three-year period, *Acta Psychiatria Scandinavica,* 1964, 40, (180), 373-382.
100. GEORGE J.R., MICHAELS T.J., SEVELIUS J., WILLIAMS M.T. : The psychedelic renaissance and the limitations of a White-dominant medical framework : a call for indigenous and ethnic minority inclusion*, Journal of Psychedelic Studies*, 2019, 12 p.
Doi : 10.1556/2054.2019.015
101. GERARD F. : Pain, Death and LSD, A Retrospective of the Work of Dr Eric Kast, in *Psychedelic Monographs and Essays*, 6 vols, Boynton Beach P.M. & E., 1990, V, iv, 114-121.
102. GIRN M., CHRISTOFF K. : Expanding the Scientific Study of Self-Experience with Psychedelics, *Journal of Consciousness Studies*, 2018, 25, (11–12), 131–154.

103. GOLDSMITH N.M. : The Ten Lessons of Psychedelic Psychotherapy, Rediscovered, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 2)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, London, 2007, 107-142.
104. GREER G.R., TOLBERT R.A. : Subjective reports of the effects of MDMA in a clinical setting, *Journal of Psychoactive Drugs,* 1986, 18, (4), 319-327.
105. GREER G.R., TOLBERT R.A. : The therapeutic use of MDMA, in « *Ecstasy : The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA »*, S.J. Peroutka ed., Holland, Kluwer, 1990.
106. GREER G.R., TOLBERT R.A. : A method of conducing therapeutic sessions with MDMA, *Journal of Psychoactive Drugs*, 1998, 30, (4), 371-379.
107. GREER G., TOLBERT R. : Therapeutic Uses of MDMA, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 1)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, 2007, 141-154.
108. GRIFFITHS R.R. et al. : Psychopharmacology of Psilocybin in Cancer Patients, *ClinicalTrials.gov*, NCT00465595, 2007-2016.
109. GRIFFITHS R.R., JOHNSON M.W., CARDUCCI M.A., UMBRICHT A., RICHARDS W.A., RICHARDS B.D., COSIMANO M.P., KLINEDINST M.A. : Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer : A randomized double-blind trial, *Journal of Psychopharmacology*, 2016, 30, 12, 1181– 1197.
Doi : 10.1177/0269881116675513
110. GRINSPOON L., BAKALAR J.B. : The Psychedelic Drug Therapies, *Current Psychiatric Therapies*, 1981, 20, 275-283.
111. GRINSPOON L., BAKALAR J.B. : Introduction, in « *Psychedelic Reflections* », 1983, 11-15.
112. GRINSPOON L., BAKALAR J.B. : History and Patterns of Psychedelic Drug Use, in « *Psychedelic Reflections »*, 1983, 16-23.
113. GRINSPOON L., BAKALAR J.B. : Psychedelic Drugs in Psychiatry, in « *Psychedelic Reflections* », 1983, 131-142.
114. GRINSPOON L., BAKALAR J.B. : A Note on Adverse Effects, in « *Psychedelic Reflections* », 1983, 124-130.
115. GRINSPOON L., BAKALAR J.B. : Afterword, in « *Psychedelic Reflections »*, 1983, 253-259.
116. GRINSPOON L., BAKALAR J.B. : Can drugs be used to enhance the psychotherapeutic process ?, *American Journal of Psychotherapy,* 1986, 40, (3), 393.
117. GRINSPOON L., BAKALAR J.B. : Psychedelic Drugs Reconsidered, Basic Books, New York/Lindesmith Center, New York, 1979/1997.
118. GRINSPOON L., BAKALAR J.B. : Therapeutic uses, in « *Psychedelic Drugs Reconsidered* », The Lindesmith Center, New York, 1997, 192-237.
119. GRINSPOON L., BAKALAR J.B. : Adverse Effects and their Treatment (Chapter 5), in « *Psychedelic Drugs Reconsidered* », The Lindesmith Center, New York, 1997.
120. GRINSPOON L., DOBLIN R. : Psychedelics as catalysts of insight-oriented psychotherapy, *Social Research*, 2001, 68, (3), 677–695.
121. GROB C. : Psychiatric research with hallucinogens : What have we learned ? *The Yearbook for Etnomedicine and the Study of Consciousness,* 1994, Issue 3.
122. GROB C. S. : Psychiatric research with hallucinogens : what have we learned ?, *The Heffter Review of Psychedelic Research*, 1998, 1, 8-20.

123. GROB C.S. : The use of psilocybin in patients with advanced cancer and existential anxiety, in M.J. Winkelman & T.B. Roberts (Eds.) « *Psychedelic medicine : New evidence for hallucinogenic substances as treatments* », (1 st ed.), Praeger Publishers, 2007, 205-216.
124. GROB C.S., DANFORTH A.L., CHOPRA G.S., HAGERTY M., McKAY C.R., HALBERSTADT A.L., et al. : Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer, *Archives of General Psychiatry*, 2011, 68, 71-78.
125. GROF S. : Psycholytic and Psychedelic Therapy with LSD : Toward an Integration of Approaches, Unpubl. paper presented at the *5th congress of the European Medical Society of Psycholytic Therapy* (EPT) in Frankfurt (Germany) 1967.
126. GROF S., SOSKIN R.A., RICHARDS W.A., KURLAND A.A. : DPT as an adjunct in psychotherapy of alcoholics, *International Pharmacopsychiatry*, 1973, 8, 104–115.
127. GROF S. Realms of the human unconscious : Observations from LSD research, New York, Viking Press, 1975.
128. GROF S. : LSD psychotherapy : Exploring the frontiers of the hidden mind, Alameda, CA, Hunter House, 1994, c1980.
129. GROF S. : LSD psychotherapy, Santa Cruz, CA, Mutidisciplinary Association for Psychedelic Studies, 2001.
130. GROF S. : The principle of LSD psychotherapy, in « *LSD Psychotherapy »,* Multidisciplinary Association for Psychedelic Studies, Sarasota, FL, 2001. (now Santa Cruz, CA.)
131. GROF S. : Personality of the Therapist or Guide, pages 87-101, in « *LSD Psychotherapy »,* Multidisciplinary Association for Psychedelic Studies, Sarasota, FL, 2001. (now Santa Cruz, CA.)
132. GROF S. : The Ultimate Journey : Consciousness and the Mystery of Death, Multidisciplinary Association for Psychedelic Studies, Santa Cruz, CA, 2006.
133. GROF S. : New Perspectives in Understanding and Treatment of Emotional Disorders, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 2)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, London, 2007, 255-286.
134. HARRIES-REES K. : Taking a medical trip, Chemistry World, 2007, 68-71.
135. HARTOGSOHN I. : Set and setting, psychedelics and the placebo response : An extra-pharmacological perspective on psychopharmacology, *Journal of Psychopharmacology*, 2016, 30, (12), 1259–1267.
136. HARTOGSOHN I. : Constructing drug effects : A history of set and setting, *Drug Science, Policy and Law*, 2017, 3, 1–17.
137. HARTOGSOHN I. : The meaning-enhancing properties of psychedelics and their mediator role in psychedelic therapy, spirituality and creativity, *Frontiers in Neuroscience*, 2018, 12, 129.
138. HENTZEN A., PASSIE T. : The Pharmacology of LSD : A Critical Review, Beckley Foundation and Oxford University Press, 2010.
139. HOFFER A. : Treatment of psychosis with LSD, in Gamage J.R., Zerkin E.L. (eds) *"Hallucinogenic drug research: impact on science and society*", Stash Press, Beloit, 1970.
140. HOFMANN A. : LSD, mon enfant terrible (LSD, mein Sorgenkind, LSD, My Problem Child), Ernst Klett Ed., Stuttgart, 1979, McGraw-Hill Book Company, 1980 (trad. Anglaise), Gris Banal Ed., 1989 (trad. Française), Editions du Lézard, 1997.
141. HORGAN J. : Psychedelic medicine : Mind bending, health giving, *New Scientist*, 26 February 2005.

142. HOVMAND O.R. : Medical Psychedelics. The evidence-based textbook about the clinical applications of LSD, psilocybin, ayahuasca, DMT, MDMA and ketamine, *O.R. Hovmand editor*, 2019, www.medicalpsychedelics.net
143. IBRAHIM L., DIAZ GRANADOS, N., FRANCO-CHAVES J. et al. : Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study, *Neuropsycho-pharmacology*, 2012, 37, 1526-1533.
144. INGOLD F.R., SUEUR C., KAPLAN C.D. : Contribution à une exploration des propriétés thérapeutiques du cannabis, *Annales médico-psychologiques. Revue psychiatrique*, 2015, 173, (5), 453-459. http://dx.doi.org/10.1016/j.amp.2015.04.001
145. INSERRA A. : Current status of psychedelic therapy in Australia and New Zealand : Are we falling behind ? *Australian and New Zealand Journal of Psychiatry,* 2019, 53, 190-192.
146. ISERSON K.V. : « Go Ask Alice » : The case for Researching Schedule I Drugs, *Cambridge Quaterly of Healthcare Ethics*, 2019, 28, 168-177. Doi : 10.1017/S0963180118000518
147. JAMES E., ROBERTSHAW T.L., WESTWELL A.D. : Emerging from the dark side : new therapeutic applications of scheduled psychoactive substances, *Future Medicinal Chemistry*, February 2019, 4 p. Doi : 10.4155/fmc-2018-0447
148. JANIGER O. : The use of hallucinogenic agents in psychiatry, *Californian Clinician,* 1960, 56, 222-224, 251-259
149. JANOS B.K., PETER K. : Research ethics aspects of experimentation with LSD on human subjects : a historical and ethical review, *Medecine, Health Care and Philosophy*, 2018, 11 p. Doi : 10.1007/s11019-018-9871-9
150. JEROME L., MOJEIKO V., DOBLIN R. : Afterword : the psychedelic research renaissance – A review of recent Psychedelic Psychotherapy Research, in "*LSD Psychotherapy*", MAPS, CA, USA, 361 – 373.
151. JEROME L., FEDUCCIA A.A., WANG J.B., HAMILTON S., YAZAR-KLOSINSKI B., EMERSON A., MITHOEFER M.C., DOBLINS R. : Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials, *Psychopharmacology*, 2020, 237, 2485–2497. Doi : 10.1007/s00213-020-05548-2
152. JOHNSON B.A., ROACHE J.D., JAVORS M.A., Di CLEMENTE C.C., PRIHODA T.J., BORDNICK P.S., AIT-DAOUD N., HENSLER J. : Ondansetron for reduction of drinking among biologically predisposed alcoholic patients, *JAMA*, 2000, 284, 963-971.
153. JOHNSON M.W., RICHARDS W.A., GRIFFITHS R.R. : Human Hallucinogen Research : Guidelines for Safety, *Journal of Psychopharmacology,* 2008, 22, (6), 603-620. Doi : 10.1177/0269881108093587
154. JOHNSON M.W., GRIFFITHS R.R. : Potential therapeutic effects of psilocybin, *Neurotherapeutics*, 2017, 14, 734–740. doi: 10.1007/s13311-017-0542-y
155. JOHNSON M.W. : Psychiatry might need some psychedelic therapy, *International Review of Psychiatry,* Institute of Psychiatry and Johns Hopkins University, 2018, 30, 4, 285-290. https://doi.org/10.1080/09540261.2018.1509544

156. JOHNSON M.W., HENDRICKS P.S., BARRETT F.S., GRIFFITHS R.R. : Classic psychedelics : an integrative review of epidemiology, therapeutics, mystical experience and brain network function, *Pharmacology & Therapeutics*, 2019. https://doi.org/10.1016/j.pharmther.2018.11.010
157. JOHNSTAD P.G. : A dangerous method ? Psychedelic therapy at Modum Bad, Norway, 1961-76, *History of Psychiatry*, 2020, 1-10. Doi : 10.1177/0957154X19894537
158. KAFKALIDIS A. : Application thérapeutique de la Diethylamide de l'acide lysergique (Delysid ou LSD 25) sur les psychonévroses*, Annales Médico-Psychologiques*, 1963, 121, (2), 191-200.
159. KA-TZETNIK 135633 : Les Visions d'un Rescapé ou le syndrome d'Auschwitz, Hachette, Paris, 1990, 157-164.
160. KELLY J.R., BAKER A., BABIKER M., BURKE L., BRENNAN C., O'KEANE V. : The psychedelic renaissance : the next trip for psychiatry ?, *Irish Journal of Psychological Medicine*, 2019, 1-5. Doi : 10.1017/ipm.2019.39
161. KOLP E., FRIEDMAN H.L., KRUPITSKY E., JANSEN K., SYLVESTER M. : Ketamine Psychedelic Psychotherapy : Focus on its Pharmacology, Phenomenology, and Clinical Applications, *International Journal of Transpersonal Studies*, 2014, 33, (2), 84–140. Doi : 10.24972/ijts.2014.33.2.84
162. KOTLER M. : MDMA-assisted Psychotherapy in Twelve People with War and Terrorism-related Post-Traumatic Stress disorders (PTSD), MAPS MDMA/PTSD Israel, *Tel Aviv University*, 2006 April 10.
163. KRAEHENMANN R. : Dreams and Psychedelics : Neurophenomenological Comparison and Therapeutic Implications, *Current Neuropharmacology,* 2017, 15, (7), 1032-1042. Doi : 10.2174/1573413713666170619092629
164. KREBS T.S., JOHANSEN P.-Ø. : Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials, *Journal of Psychopharmacology*, 2012, 26, (7), 994–1002. Doi : 10.1177/0269881112439253
165. KREBS T.S., JOHANSEN P. O. : Psychedelics and mental health: a population study, *PLoS One*, 2013, 8, e63972
166. KREDIET E., BOSTOEN T., BREEKSEMA J., Van SCHAGEN A., PASSIE T., VERMETTEN E. : Reviewing the Potential of Psychedelics for the Treatment of PTSD, *International Journal of Neuropsychology*, 2020, 1-16. Doi : 10.1093/ijnp/pyaa018
167. KURLAND A., SAVAGE C., PAHNKE W.N., GROF S., OLSSON J.E. : LSD in the treatment of alcoholics, *Pharmacopsychiatry*, 1971, 4, (02), 83–94.
168. KURLAND A.A., GROF S., PAHNKE W.N., GOODMAN L.E. : Psychedelic drug assisted psychotherapy in patients with terminal cancer, *Journal of Thanatology,* 1972, 2, 644–691.
169. KVAM T.-M., STEWART L.H., ANDREASSEN O.A. : Psychedelic drugs in the treatment of anxiety, depression and addiction, *Tidsskriftet, Den Norske Legeforening,* November 2018. Doi : 10.4045/tidsskr.17.1110 https://www.researchgate.net/publication/332136512

170. LABATE B.C., CAVNAR C. (Eds.) : The Therapeutic Use of Ayahuasca, Springer-Verlag, Berlin, Heidelberg, 2014.
171. LABATE B.C., CAVNAR C. : Plant Medicines, Healing and Psychedelic science : Cultural perspectives, Springer Ed., 2018.
172. LANGLITZ N. : Neuropsychedelia : The Revival of Hallucinogen Research Since the Decade of the Brain, University of California Press, Berkeley and Los Angeles, California, 2013.
173. LANGLITZ N. : Psychedelics can't be tested using conventional clinical trials, *Aeon Ideas,* 2015.
https://aeon.co/ideas/psychedelics-can-t-be-tested-using-conventional-trials
174. LEVY-WILLARD A. : Rencontre avec le Professeur Baastians, in « *Les visions d'un rescapé ou le Syndrome d'Auchschwitz* », KA-TZETNIK 135633, Hachette, 1990, 157-164.
175. LETHEBY C. : The Varieties of Psychedelic Epistemology, in « *Psychedelicacies : more food for thought from Breaking Convention »,* N. Wyrd, D. Luke, A. Tollan, C. Adams and D. King (eds.), Strange Attractor Press, 2019.
176. LEUNER H. : Die experimentelle Psychose [The experimental psychosis], Berlin, Springer-Verlag, 1962.
177. LEUNER H. : Psychotherapy with hallucinogens : A clinical report with special reference to the revival of emotional phases of childhood, in R. Crocket, R.A. Sandison, A. Walk (Eds.), "*Hallucinogenic drugs and their psychotherapeutic use"* (pp. 67–73), London, H.K. Lewis, 1963.
178. LEUNER H. : Guided affective imagery (GAI), *American Journal of Psychotherapy*, 1969, 23, (1), 4–22.
179. LIECHTI M.E. : Modern Clinical Research on LSD, *Neuropsychopharmacology*, 2017, 42, 2114–2127.
Doi : 10.1038/npp.2017.86
180. LOVE S. : The Ethics of Taking the Drugs you Study. Should psychedelic scientists trip on the drugs they research ?, *VICE.com,* May 14, 2019.
https://www.vice.com/en_us/article/qv7jkx/the-ethics-of-taking-the-drugs-you-study
181. LUOMA J.B., CHWYL C., BATHJE G.J., DAVIS A.K., LANCELOTTA R. : A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy, *Journal of Psychoactive Drugs*, 2020, 1-31.
Doi : 10.1080/02791072.2020.1769878
182. MANGINI M. : Treatment of alcoholism using psychedelic drugs : a review of the program of research, *Journal of Psychoactive Drugs*, 1998, 30, (4), 381-418.
183. MARSDEN R., LUKOFF D. : Transpersonal Healing with Hallucinogens, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 2)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, London, 2007, 287-306.
184. MASON N.L., KUYPERS K.P.C. : Mental Health of a self-selected sample of psychedelic users and self-medication practices with psychedelics, *Journal of Psychedelic Studies*, 2018, 2, (1), 45-52.
Doi : 10.1556/2054.2018.006
185. MASON N.L., DOLDER P.C., KUYPERS K.P.C. : Reported effects of psychedelic use on those with low well-being given various emotional states and social contexts, *Drug Science, Policy and Law,* 2020, 6, 1-11
Doi : 10.1177/2050324519900068

186. MacLEAN J.R., MacDONALD D.C., OGDEN F., WILBY E. : LSD 25 and Mescaline as Therapeutic Adjuvants, in "*The Use of LSD in Psychotherapy and Alcoholism",* ed. H. Abramson, Bobbs-Merrill Company, New York, 1967, 407-429.
187. McKENNA D. J. : Clinical investigations of the therapeutic potential of ayahuasca : rationale and regulatory challenges, *Pharmacology & Therapeutics*, 2004, 102, 111-129. Doi : 10.1016/j.pharmthera.2004.03.002
188. MELECHI A. : Drugs of liberation : from psychiatry to psychedelia, in A. Melechi (Ed.) « *Psychedelia Britannica : hallucinogenic drugs in Britain* », London, Turnaround, 1997, 21-52.
189. MERKUR D. : A Psychoanalytic Approach to Psychedelic Psychotherapy, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 2)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, London, 2007, 195-212.
190. METZNER R. : The ecstatic adventure, Macmillan Ed., USA, 1968.
191. METZNER R., LEARY T. : Sur la programmation des expériences psychédéliques, in J.P. Guimard et al. (Eds.) « *Mandala. Essai sur l'Expérience Hallucinogène* », 1969, 269-284.
192. METZNER R. : States of consciousness and transpersonal psychology as altered states of consciousness, in "*Existential-and Phenomenological Perspectives in Psychology*", R. Vallee & S. Halling Ed., Plenum Press, New York, USA, 1989.
193. METZNER R. : Therapeutic applications of altered states of consciousness (ASC), in "*Worlds of consciousness*", vol. 5, Abstracts and selected papers, First International Congress of the European College for the Study of Consciousness (ECSC), Göttingen (Germany), September 24-27 1992, VWB, Berlin, 1995, 185-193.
194. METZNER R. : Addiction and transcendence as altered states of consciousness, in "*Worlds of consciousness*", vol. 5, Abstracts and selected papers, First International Congress of the European College for the Study of Consciousness (ECSC), Göttingen (Germany), September 24-27 1992, VWB, Berlin, 1995, 215-231.
195. METZNER R. : Hallucinogenic drugs and plants in psychotherapy and shamanism, *Journal of Psychoactive Drugs*, 1998, 30, 4, 333-341.
196. MICHAELS T.I., PURDON J., COLLINS A., WILLIAMS M.T. : Inclusion of people of color in psychedelic-assisted psychotherapy : a review of the litterature, *BMC Psychiatry*, 2018, 18, 245, 14 pp. https://doi.org/10.1186/s12888-018-1824-6
197. MILLER R.L. : Psychedelic Medicine. The Healing Powers of LSD, MDMA, Psilocybin, and Ayahuasca, with texts of Dennis McKenna, Stanislav Grof, James Fadiman, Rick Doblin, Julie Holland and others, Park Street Press, Rochester, Vermont, USA, Toronto, Canada, 2017.
198. MITHOEFER M. : MDMA-assisted Psychotherapy for the Treatment of Post-traumatic Stress Disorder, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 1)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, London, 2007, 125-140. (155-176).
199. MITHOEFER M.C., WAGNER M.Y., MITHOEFER A.T., JEROME L., DOBLIN R. : The Safety and Efficacy of {+/-} 3,4-methylenedioxymethamphetamine-assisted Psychotherapy in Subjects with Chronic, Treatment-resistant Posttraumatic Stress Disorder : The First Randomized Controlled Pilot Study*, Psychopharmacology*, 2011, 25, (4), 439-452.
200. MITHOEFER M.C., WAGNER M.T., MITHOEFER A.T., JEROME L., MARTIN S.F., YAZAR-KLOSINSKI B., MICHEL Y., BREWERTON T.D., DOBLIN R. : Durability of

improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study, *Journal of Psychopharmacology*, 2013, 27, 28–39.
201. MITHOEFER M.C. : MDMA-Assisted Psychotherapy : How Different is it from Other Psychotherapy ?, *MAPS Bulletin Special Edition*, Spring 2013, 10-14.
202. MITHOEFER M.C., GROB C.S., BREWERTON T.D. : Novel psychopharmacological therapies for psychiatric disorders : psilocybin and MDMA, *Lancet Psychiatry*, 2016, 3, 481-488.
Doi : 10.1016/S2215-0366(15)00576-3
203. MITHOEFER M.C. : A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder, *MAPS*, Version 8.1: 22 May 2017. https://maps.org/research/mdma/mdma-research-timeline/4887-a-manual-for-mdma-assisted-psychotherapy-in-the-treatment-of-ptsd
204. MITHOEFER M.C., MITHOEFER A.T., FEDUCCIA A.A. et al. : 3,4-Methylene-dioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers : a randomized, double-blind, dose-response, Phase II clinical trial, *Lancet Psychiatry*, 2018, 5, 486–497.
205. MOGAR R.E., ALDRICH R.W. : The Use of Psychedelic Agents with Autistic Schizophrenic Children, *Psychedelic Review*, 1969, Vol. 10, 5-13.
206. MOI G. : Histoire de la kétamine et du psychédélisme, *Annales Médico-Psychologiques*, 2017, 175, 661-664.
Doi : 10.1016/j.amp.2017.07.002
207. MONTAGNE M. : Psychedelic Therapy for the Treatment of Depression, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 1)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, London, 2007, 177-190.
208. MORENO F.A., DELGADO P., GELENBERG A.J. : Effects of Psilocybin in Obsessive-Compulsive Disorder.
http://www.maps.org/research/psilo/azproto.html
209. MORENO F.A., WIEGAND C.B., TAITANO E.K., DELGADO P.L. : Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder, *Journal of Clinical Psychiatry*, 2006, 67, (11), 1735-1740.
210. MORENO F.A., DELGADO P.L. : Psilocybin Treatment of Obsessive-Compulsive Disorder, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 1)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, 2007, 125-140.
211. MORRIS K. : Research on Psychedelics Moves into the Mainstream, *The Lancet*, 2008, 371, 1491-1492.
212. MORRIS K. : Hallucinogen Research Inspired Neurotheology, *The Lancet Neurology,* 2006, 5, (9), p 732.
213. MURPHY T. : Psychedelics for Mental Illness : The Evidence to Date, Medscape, Mars 12, 2020. www.medscape.com/viewarticle/926694
214. NICHOLS D.E., JOHNSON M.W., NICHOLS C.D. : Psychedelics as medicines : an emerging new paradigm, *Clinical Pharmacology & Therapeutics*, 2017, 101, 209–219.
Doi : 10.1002/cpt.557
215. NIDA : MDMA/Ecstasy Research : Advances, Challenges, Future Directions. A Scientific Conférence, July 19-20, 2001, *National Institue of Health, National Institute on Drug Abuse*.

https://archives.drugabuse.gov/meetings/MDMA/MDMAAbs2.html
216. OEHEN P., TRABER R., WIDMER V., SCHNYDER U. : A randomized, controlled pilot study of MDMA (+/− 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD), *Journal of Psychopharmacology*, 2013, 27, 40–52.
217. OLIEVENSTEIN S.C. : Contribution à l'étude du LSD 25 en clinique Psychiatrique, Thèse de Médecine, Paris, 1967.
218. ONA G., TRONCOSO S. : Long-lasting analgesic effect of the psychedelic drug changa : A case report, *Journal of Psychedelic Studies*, 2019, 3, (1), 7–13. Doi: 10.1556/2054.2019.001
219. ORAM M. : Efficacy and Enlighttenment : LSD Psychotherapy and the Drug Amendments of 1962, *Journal of History of Medicine and Allied Sciences*, 2014, 69, 2, 221-250. Doi : 10.1093/jhmas/jrs050
220. ORAM M. : Prohibited or regulated ? LSD psychotherapy and the United States Food and Drug Administration, *History of Psychiatry*, 2016, 27, (3), 290-306. Doi : 10.1177/0957154X16648822
221. ORAM M. : The Trials of Psychedelic Therapy. LSD Psychotherapy in America, John Hopkins University Press, 2018.
222. OSSEBAARD H.C. : A Dissertation On the Constructive (Therapeutic and Religious) Use of Psychedelics : A Request for Support, *Revue du MAPS,* 2001, vol XI, n°2, 12-13.
223. OT'ALORA M., GRIGSBY J., POULTER, B., Van DERVEER III J.W., GIRON S.G. JEROME L., FEDUCCIA A.A., HAMILTON S., YAZAR-KLOSINSKI B., EMERSON A., MITHOEFER M.C., DOBLIN R. : 3,4-Methylenedioxymethamphetamine assisted psychotherapy for treatment of chronic posttraumatic stress disorder : A randomized phase 2 controlled trial, *Journal of Psychopharmacology*, 2018, 1-13. Doi : 10.1177/0269881118806297
224. PASSIE T. : Psycholytic and Psychedelic Therapy Research 1931-1995 : A Complete International Bibliography, Laurentis Publishers, Hannover, Germany, Lists 687 studies, 1997.
225. PASSIE T. : Contemporary Psychedelic Therapy : An Overview, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 1)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, 2007, 45-68.
226. PASSIE T. : The Science of Microdosing Psychedelics, Falmouth, Psychedelic Press, 2018.
227. PERRINE D. : The Chemistry of Mind-altering Drugs : History, Pharmacology, and Cultural Context, American Chemical Society, Washington, DC, 1996.
228. PHELPS J. : Developing Guidelines and Competencies for the training of Psychedelic Therapists, *Journal of Humanistic Psychology*, 2017, 38 p. Doi : 10.1177/0022167817711304
229. PHIFER B. : A review of the research and theological implications of the use of psychedelic drugs with terminal cancer patients, *Journal of Drug Issues,* 1997, 7, (3), 287-292.
230. POLLAN M. : How To Change Your Mind. The New Science of Psychedelics, Penguin Books, UK/USA/Canada/Ireland/Australia…, 2018.

231. POSTRÁNECKÁ Z., VEJMOLA C. and TYLŠ F. : Psychedelic therapy in the Czech Republic: A theoretical concept or a realistic goal?, *Journal of Psychedelic Studies*, 2019, 3, (1), 19–31.
Doi : 10.1556/2054.2019.003
232. QUETIN A.-M. : La psilocybine en Psychiatrie clinique et expérimentale, Thèse de Médecine, juin 1960, Paris .
233. RAISON C.L. : Editorial. Everything old is new again : are psychedelic medicines poised to take mental health by storm ?, *Acta Psychiatrica Scandinavica*, 2018, 138, 365-367.
Doi : 10.1111/acps.12975
234. REICHE S., HERMLE L., GUTWINSKI S., JUNGABERLE H., GASSER P. MAJIC T. : Serotoninergic hallucinogens in treatment of anxiety and depression in patients suffering from a life-threatening disease : A systematic review, *Progress in Neuropsychopharmacology and Biological Psychiatry*, 2018, 81, 1-10.
Doi : 10.1016/j.pnpbp.2017.09.012
235. REIFF C.M., RICHMAN E.E., NEMEROFF C.B., CARPENTER L.L., WIDGE A.S., RODRIGUEZ C.I., KALIN N.H., McDONALD W.M. et al. : Psychedelics and Psychedelic-Assisted Psychotherapy, *AJP in Advance*, 2019, 1-20. Doi : 10.1176/appi.ajp.2019.19010035
236. RHEAD J.C. : The Use of Psychedelic Drugs in the Treatment of Severely Disturbed Children : A Review, *Journal of Psychedelic Drugs,* 1977, 9, (2), 95-101.
237. RICHARDS W.A., RHEAD J.C., DiLEO F.B., YENSEN R., KURLAND A.A. : The peak experience variable in DPT-assisted psychotherapy with cancer patients, *Journal of Psychoactive Drugs*, 1977, 9, 1–10.
doi: 10.1080/02791072.1977.10472020
238. RIEDLINGER T.J., RIEDLINGER J.E. : Psychedelic and Entactogenic Drugs in the Treatment of Depression, *Journal of Psychoactive Drugs*, 1994, 26, (1), 41-55.
239. ROBERTS T.B. : Multistate Mind, Part 3 in « *Psychedelic Horizons : Snow White, Immune System, Multistate Mind, Enlarging Education »,* Imprint-Academic, Exeter, UK, 2006.
240. ROBERTS T.B. : The Experience that Alters All Others. Raising Values, Chapters 2 and 3 in « *The Fruitful Mind : Our Psychedelic Future of Enhanced Cognition, Revived Religion, De-fanged Death, and Invigorated Academia, Business, and Education* », Inner Traditions, Rochester, VT, 2012.
241. ROBERTS T.B. : Enhancing Cognition, Boosting Intelligence, Expanding Cognitive Studies, Chapter 9 in *« The Fruitful Mind* », Inner Traditions, Rochester, VT, 2012.
242. ROBERTS T.B. : Chilling effects 1 : Grofian Psychocritiscism, in J. H. Ellens & T. B. Roberts (Eds.), « *The psychedelic policy quagmire : Health, law, freedom, and society* » (pp. 20-23), Santa Barbara, CA, ABC/CLIO, 2015.
243. ROBERTS T.B. : Chilling effects 2 : Brief communiques from the psychedelic intellectual frontier, in J. H. Ellens & T. B. Roberts (Eds.), « *The Psychedelic Policy Quagmire : Health, law, freedom, and society* », Santa Barbara, CA, ABC/CLIO, 2015.
244. ROBERTS T.B. : Psychedelics as Ideagens – Seeding Our Minds in the Psychedelic Renaissance, www.niu.academia.edu/ThomasRoberts , 2018.
245. ROSEMAN L., NUTT D.J., CARHART-HARRIS R.L. : Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression, *Frontiers in Pharmacology,* 2018, 8, article 974.
Doi : 10.3389/fphar.2017.00974

246. ROSENBAUM D., WEISSMAN C., HAPKE E., HUI K., PETRANKER R., DINH-WILLIAMS L.-A. et al. : Microdosing psychedelic substances : demographics, psychiatric comorbidities, and comorbid substance use, *in preparation*.
247. ROSS S., MacLEAN J.R., MacDONALD D.C., OGDEN F., WILBY E. : LSD 25 and Mescaline as Therapeutic Adjuvants, in "*The Use of LSD in Psychotherapy and Alcoholism*", Bobbs-Merrill Company Inc., Indianapolis, 1967, 407-429.
248. ROSS S., BOSSIS A., GUSS J., AGIN-LIEBES G., MALONE T., COHEN B., MENNENGA S.E., BELSER A., KALLIONTZI K., BABB J., SU Z., CORBY P., SCHMIDT B.L. : Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer : a randomized controlled trial, *Journal of Psychopharmacology*, 2016, 30, (12), 1165– 1180. Doi : 10.1177/0269881116675512 ClinicalTrials.gov : NCT00957359
249. RUCKER J.J.H., JELEN L.A., FLYNN S., FROWDE K.D., YOUNG A.H. : Psychedelics in the treatment of unipolar mood disorders : a systematic review, *Journal of Psychopharmacology*, 2016, 1-10. Doi : 10.1177/0269881116679368
250. RUCKER J.J.H., ILIFF J., NUTT D.J. : Psychiatry & the psychedelic drugs. Past, present & future, *Neuropharmacology*, 2018, 142, 200e218. Doi : 10.1016/j.neuropharm.2017.12.040
251. SALIH L.H., KAUSHIK A. : Mini Review on Psychedelic Drugs : Illumination on the Hidden Aspects of Mind, *American Journal of Phytomedicine and Clinical Therapeutics*, 2013, 1, 5, 432-444.
252. SANDISON R.A., SPENCER A.M., WHITELAW J.D. : The therapeutic values of lysergic acid diethylamide in mental illness, *Journal of Mental Science*, 1954, 100, 491-507.
253. SANDISON R.A. : Psychological aspects of the LSD treatment of neuroses, *Journal of Mental Science*, 1954, 100, 508-515.
254. SANDISON R.A., WHITELAW J.D.A. : Further studies in the therapeutic value of lysergic acid diethylamid in mental illness, *Journal of Mental Science,* 1957, 103, 332-343.
255. SANDISON R.A. : Certainty and uncertainty in the use of LSD treatment of psychoneurosis, in R Crocket, R.A. Sandison and A. Wolk (eds) « *Hallucinogenic drugs and their psychotherapeutic use* », London, H.K. Lewis, 1963, pp 33-36.
256. SCHARFETTER A. : Athena Awakening : A Theoretical Exploration of Cathartic Integration within Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, San Fancisco, CA, 2017.
257. SCHENBERG E.E. : Psychedelic-Assisted Psychotherapy : A Paradigm Shift in Psychiatric Research and Development, *Frontiers in Pharmacology,* 2018, 11 pp. Doi : 10.3389/fphar.2018.00733
258. SCHULTES E., HOFMANN A., RATSCH C. : Plants of Gods, Rochester, Vermont Healing Arts Press, 1998.
259. SCOTT G., CARHART-HARRIS R.L. : Psychedelics as a treatment for disorders of consciousness, *Neuroscience of Consciousness*, 2019, 5, (1), niz003. Doi : 10.1093/nc/niz003
260. SELLERS E.M., LEIDERMANN D.B. : Psychedelic Drugs as Therapeutics : No Illusions About the Challenges, Clinical Pharmacology & Therapeutics, 2018, 103, (4), 561-564. Doi : 10.1002/cpt.776

261. SESSA B. : Can psychedelics have a role in psychiatry once again ?, *British Journal of Psychiatry,* 2005, 186, 457-458
Doi : 10.1192/bjp.186.6.457
262. SESSA B. : Are psychedelic drug treatments seeing a comeback in psychiatry, *Progress in Neurology and Psychiatry,* 2008, 12, (8), 5-10.
Doi : 10.1002/pnp.94
263. SESSA B. : Is it time to revisit the role of psychedelic drug in enhancing human creativity ?, *Journal of Psychopharmacology*, 2008.
264. SESSA B. : Shaping the renaissance of psychedelic research, *Lancet*, 2012, 380, (9838), 200-201.
Doi : 10.1016/S0140-6736(12)60600-X
265. SESSA B. : The Psychedelic Renaissance. Reassessing the Role of Psychedelic Drugs, in 21st Century Psychiatry and Society*,* London, UK, Muswell Hill Press, 2012.
266. SESSA B. : Why Psychiatry needs psychedelics and psychedelics need psychiatry, *Journal of Psychoactive Drugs*, 2014, 46, (1), 57-62.
Doi : 10.1080/02791072.2014.877322
267. SESSA B. : Can 3,4-methylenedioxymethamphetamine therapy, be used to treat alcohol use disorder ?, *Journal of Psychedelic Studies,* 2017, 1, (1), 1-9.
Doi : 10.1556/2054.01.2016.003
268. SESSA B. : The History of Psychedelics in Medecine, 2016, in « *Handbuch Psychoaktive Substanzen* », Springer-Verlag GmbH, Deutschland, 1-26.
269. SESSA B. : Why Psychiatry Needs 3,4-methylenedioxymethamphetamine : A Child Psychiatrist 's Perspective, *Neurotherapeutics,* 2017, 14, (3), 741-749.
Doi : 10.1007/s13311-017-0531-1
270. SESSA B., HIGBED L., NUTT D. : A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy, *Frontiers in Psychiatry*, 2019, 7 p.
Doi : 10.3389/fpsyt.2019.00138
271. SEWEL R.A., HALPERN J.H. : Response of Cluster Headache to Psilocybin and LSD, , in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 1)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, 2007, 97-124.
272. SHAGASS C., BITTLE R.M. : Therapeutic Effect of LSD : A Follow-up Study, *Journal of Nervous and Mental Disease*, 1967, 144, (6), 471-478.
273. SHANON B. : Antipodes of the Mind : Charting the Phenomenology of the Ayahuasca Experience, Oxford, UK, Oxford University Press, 2002.
274. SHANON B. : Moments of Insight, Healing, and Transformation : A Cognitive Phenomenological Analysis, Chapter 4, in « *The Therapeutic Use of Ayahuasca* », B.C. Labate and C. Cavnar, Springer Berlin Heidelberg, 2014, 59-132.
275. SHERWOOD J.N., STOLAROFF M.J., HARMAN W.W. : The psychedelic experience – a new concept in psychotherapy*, Journal of Neuropsychiatry*, 1962, 4, 69-80.
276. SHERWOOD A.M., PRISINZANO T.E. : Novel psychotherapeutics – a cautiously optimistic focus on hallucinogens, *Expert Review of Clinical Pharmacology*, 2018, 11, (1), 1-3.
Doi : 10.1080/17512433.2018.1415755
277.
278. SHULGIN Al., SHULGIN An. : PIHKAL, A Chemical Love Story, Transform Press, Berkeley, CA, 1991, 1995.

279. SHULGIN Al., SHULGIN An. : TIHKAL, The Continuation, Transform Press, Berkeley, CA, 1997.
280. SHULGIN Al., SHULGIN An. : A New Vocabulary, in « *Entheogens and the Future of Religion* », Council on Spiritual Practices, 1997.
281. SIGAFOOS J., GRENN V.A., EDRISINHA C., LANCIONI G.E. : Flashback to the 1960s : LSD in the treatment of autism, *Developmental Neurorehabilitation*, 2007, 10, 75-81.
282. SLOSHOWER J. : Integrating Psychedelic Medicines and Psychiatry : Theory and Methods of a Model Clinic, Chapter 7, in « *Plant Medicines, Healing and Psychedelic Science : Cultural Perspectives* », Beatriz Caiuby Labate & Clancy Cavnar (Eds), 2018, Springer International Publishing AG.
Doi : 10.1007/978-3-319-76720-8_7
https://www.youtube.com/watch?v=9uvFSCxcl3I&feature=youtu.be
283. SMITH C.M. : Some reflections on the Possible Therapeutic Effects of the Hallucinogens. With Special Reference to Alcoholism, *Quaterly Journal of Studies on Alcohol*, 1959, 20, 292-301.
284. SNELDERS S. : The LSD Therapy Career of Jan Bastiaans, M.D., *MAPS Bulletin*, 1998, 8, (1), 18-20.
285. SNELDERS S. : LSD-therapie in Nederland : de experimenteel-psychiatrische benadering van J. Bastiaans, G.W. Arendsen Hein en C.H. van Rhijn, Amsterdam, Candide, 2000, pp 103-160.
286. SNELDERS S., KAPLAN C. : LSD Therapy in Dutch Psychiatry : Changing Socio-Political settings and medical sets, *Medical History*, 2002, 46, (2), 221-240.
287. SNELDERS S., KAPLAN C., PIETERS T. : On Cannabis, Chloral Hydrate, and Career Cycles of psychotropic drugs in Medicine, *Bulletin of the History of Medicine*, 2006, 80, (1), 95-114.
288. SOSKIN R.A. et al. : Low Doses of Dipropyltryptamine in Psychotherapy, *Archives of General Psychiatry,* 1973, 28, (6), 817-821.
289. SOSKIN R.A. : Dipropyltryptamine in psychotherapy, *Current Psychiatric Therapies*, 1975, 15, 147-156.
290. STANSBURY K.A. : The Influence of Psychedelic Induced Ego-Dissolution on Self-Compassion, Thesis, School of Social Work California State University, Long Beach, *B.A., 2011, California State University, Dominguez Hills,* May 2019.
291. STOLAROFF M.J., WELLS C.W. : Preliminary Results with New Psychoactive Agents 2C-T-2 and 2C-T-7, *Yearbook for Ethnomedicine*, 1993, (2), 99-117.
292. STRASSMAN R.J. : Human hallucinogenic drug research : regulatory, clinical, and scientific issues, *NIDA Research Monography*, 1994, 146, 92-123.
293. SUEUR C. et al. Les substances hallucinogènes et leurs usages thérapeutiques. Revue de la littérature, partie 1, 1999, et partie 2, 2000, *Revue Toxibase*
http://www.cirddalsace.fr/docs/revue_toxibase/pdf/dossier_halluci.pdf
http://www.cirddalsace.fr/docs/revue_toxibase/pdf/dossier_halluc2.pdf
294. SUEUR C. : La recherche sur les capacités thérapeutiques des « substances hallucinogènes », *Chimères*, 2017, 91, 121-138.
295. SUEUR C. : Etat des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21° siècle, *Psychotropes*, 2017, 24, (3-4), 125-163.
296. SWANSON L.R. : Unifying Theories of Psychedelic Drug Effects, *Frontiers in Pharmacology,* 2018, 23 pp.
Doi : 10.3389/fphar.2018.00172
297. THOMAS K., MALCOLM B., LASTRA D. : Psilocybin-assisted therapy : A review

of a novel treatment for psychiatric disorders, *Journal of Psychoactive Drugs*, 2017, 49, (5), 446–455.
Doi : 10.1080/02791072.2017.1320734
298. TOSCANO A. : Étude auto-expérimentale avec deux drogues psychodysleptiques LSD 25 et psilocybine : comparaison des résultats, Mémoire de Psychiatrie, 1959, Paris.
299. TUPPER K.W. : Entheogens and Existential Intelligence : The Use of Plant Teachers as Cognitive Tools, *Canadian journal of Education*, 2002, 27, (4), 499-516.
300. TUPPER K.W., WOOD E., YENSEN R., JOHNSON M.W. : Psychedelic medicine : a re-emerging therapeutic paradigm, *Canadian Medical Association Journal*, 2015, 187, 1054-1059
Doi : 10.1503/cmaj.141124
301. TURNS D., DENBER H.C. : Mescaline and Psychotherapy, *Arzneimittelforschung*, 1966, 16, (2), 251-253.
302. UNGER S.M. : Mescaline, LSD, Psilocybin and Personality Change, chapter II, in "*LSD-The Consciousness-Expanding Drug*", *Psychiatry : Journal for the Study of Interpersonal Processes*, 1963, Vol. 26, No. 2, 200-228.
303. UTHAUG M.V., LANCELOTTA R., van OORSOUW K., KUYPERS K.P.C., MASON N., RAK J., ŠULAKOVA A., JUROK R., M. MARYSKA M., KUCHAR M., T. PALENICEK T., RIBA J., RAMAEKERS J.G. : A single inhalation of vapor from dried toad secretion containing 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms, *Psychopharmacology*, 2019.
https://doi.org/10.1007/s00213-019-05236-w
304. VALLA J.P. : L'expérience hallucinogène, Masson, Paris, 1983.
305. VARLEY J. : Psychedelic-assisted therapy for anxiety and depression in the face of death : A critical review with an anthropological lens, *Journal of Psychedelic Studies*, 2019, 3, (1), 14-18
Doi : 10.1556/2054.2019.005
306. VERROUST V. : Des cannabinoïdes à la psilocybine : des psychotropes thérapeutiques ?, in « *24e rencontres du RESPAAD – GRECC* », 21 juin 2019, Paris.
307. VOLLENWEIDER F.X., KOMETER M. : The neurobiology of psychedelic drugs: implications for the treatment of mood disorders, *Nature Reviews Neuroscience*, 2010, 11, (9), 642-651.
Doi : 10.1038/nrm2884
308. WALSH R., GROB C.S. : Psychological Health and Growth, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 2)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, London, 2007, 213-226.
309. WALSH Z., THIESSEN M.S. : Psychedelic and the new behaviourism : considering the integration of third-wave behaviour therapies with psychedelic-assisted therapy, International *Review of Psychiatry,* 2018.
Doi : 10.1080/09540261.2018.1474088
310. WEBSTER P. : Heaven and Hell Revisited, composed in 1996 for *The Psychedelic Library*.
311. WEBSTER P. : Augmenting Science with Psychedelics, Chapter 5, Manuscript, 2018, 20 p.
312. WEBSTER P. : Psychedelic Elephant, July 2019.
www.rechearchgate.net/publications/334808255

313. WHELAN A., JOHNSON M.I. : Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain : a potential role ?, *Pain Management*, 2018.
Doi : 10.2217/pmt-2017-0068
314. WILDBERGER J.I., JOHN C.N., HALLOCK R.M. : Perceptions of the medicinal value of hallucinogenic drugs among college students, *Journal of Psychedelic Studies*, 2017, 1(2), pp. 50–54
Doi : 10.1556/2054.01.2017.008
315. WILKINS L.J. : From LSD to Diametrically Opposite to Something Entirely Different : A Critical Consideration of Contrasted-Altered States of Consciousness, Thesis Presented for The Graduate Studies Council, The University of Tennessee Health Science Center, June 21, 2019.
316. WINKELMAN M. : Alternative and Traditional Medicine Approaches for Substance Programs : A Shamanic Perspective, *International Journal of Drug Policy*, 2001, 12, 337-351.
317. WINKELMAN M. : Drug Tourism or Spiritual Healing ? Ayahuasca Seekers in the Amazon, *Journal of Psychoactive Drugs*, 2005, 37, (2), 209-217.
318. WINKELMAN M., T.B. ROBERTS (Editors) : Psychedelic Medicine: New Evidence for Hallucinogenic Substances as Treatments, Volume I, Part I : The Social and Clinical Context, Part II : Medical Applications, Part III : Legal Aspects of the Medical Use, Volume II, Part I Treating Substance Abuse, Part II : Guidelines for Psychotherapeutic Applications, Part III : Transpersonal Dimension of Healing with Psychedelic Medicines, Praeger, Westport, CT./Greenwood, London, 2007.
319. WINKELMAN M.J. : Therapeutic Bases of Psychedelic Medicines : Psycho-integrative Effects, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 1)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, 2007, 1-20.
320. WINKELMAN M.J., ROBERTS T.B. : Conclusions : Guidelines for Implementing the Use of Psychedelic Medicines, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 1)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, 2007, 271-xxx.
321. WINKELMAN M.J. : Shamanic Guidelines for Psychedelic Medicine, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 2)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, London, 2007, 143-168.
322. WINKELMAN M. : Psychedelics as medicines for substance abuse rehabilitation : Evaluating treatments with LSD, peyote, ibogaine and ayahuasca, *Current Drug Abuse Reviews,* 2014, 7, (2), 101–116.
Doi : 10.2174/1874473708666150107120011
323. WINKELMAN M.J. : The Mechanism of Psychedelic Visionary Experiences : Hypotheses from Evolutionary Psychology, *Frontiers in Neuroscience*, 2017, 17 p.
Doi : 10.3389/fnins.2017.00539
324. WINKELMAN M., SESSA B. Editors : Advances in Psychedelic Medicine. State-of-the-Art. Therapeutic Applications, Praeger, ABC-CLIO, Santa Barbara California, Denver Colorado, 2019.
325. WOLFSON P.E. : Psychedelic Experiential Pharmacology : Pioneering Clinical Explorations with Salvador Roquet. An Interview with Richard Yensen, *International Journal of Transpersonal Studies*, 2014, 33, (2), 160-174.

326. YADEN D.B., GRIFFITHS R.R. : The Subjective Effects of Psychedelics are Necessary for Their Enduring Therapeutic Effects, *ACS Pharmacology & Translational Science*, 2020, A-E.
Doi : 10.1021/acsptsci.0c00194
327. YENSEN R., DiLEO F.B., RHEAD J.C., RICHARDS W.A., SOSKIN R.A., TUREK B., KURLAND A.A. : MDA-Assisted Psychotherapy with Neurotic Outpatients : A Pilot Study, *Journal of Nervous and Mental Disease*, 1976, 163, (4), 233-245.
328. YENSEN R. : LSD and Psychotherapy, *Journal of Psychoactive Drugs,* 1985, 17, (4), 267-277.
329. YENSEN R. : From Mysteries to Paradigms : Humanity's Journey from Sacred Plant to Psychedelic Drugs, *Revision*, 1988, 10, (4), 31-50.
330. YENSEN R. : From Mysteries to Paradigms : Humanity's Journey from Sacred Plant to Psychedelic Drugs, in C. Räitsch (Ed.), "*Gateway to Inner Space : Sacred plant, mysticism and psychotherapy*", Dorset, Prism Press, 1989, 11-53.
331. YENSEN R. : Thirty Years of Psychedelic research : The Spring Grove Experiment and its Sequels, *European College of Consciousness (ECBS) International Congress, Worlds of Consciousness in Göttingen*, Germany, 24-27 September 1992.
332. YENSEN R. : Perspectives on LSD & Psychotherapy : Search for a New Paradigm, *Drug Policy Foundation Conference*, Washington DC, November 20-21, 1993.
333. YENSEN R. : From Shamans and Mystics to Scientists and Psychotherapists : Interdisciplinary Perspectives on the Interaction of Psychedelics Drugs and Human Consciousness, in *Yearbook in Cross-Cultural Medicine and Psychotherapy* (Verlag), entitled « *The Constructive Potential of Psychedelics : Cross-Cultural Perspective* », 1995.
334. YENSEN R., DRYER D.A. : The Consciousness Research of Stanislas Grof : A Cosmic Portal Beyond Individuality, 1998, 23 p.
335. YENSEN R., DRYER D. : Addiction, Despair, and the Soul : Successful Psychedelic Psychotherapy, A Case Study, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 2)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, 2007, 15-28.
336. YENSEN R. : Pilgrimage to the Light ? on the Threshold of a Dream : Sacred Plants, Passionate Dedication to Ideals, and Healing, Chapter 8, in Project « *Documentary « Remembering Salvador » the Life and Work of Salvador Roquet, MD* », 2015.
https://www.researchgate.net/publication/282132139
337. YENSEN R. : Psychedelic Experiential Pharmacology : Pioneering Clinical Explorations with Salvador Roquet (How I Came to All of This: Ketamine, Admixtures and Adjuvants, Don Juan and Carlos Castaneda Too), An Interview with Richard Yensen, in Project « *Documentary « Remembering Salvador » the Life and Work of Salvador Roquet, MD* », 2015, *International Journal of Transpersonal Studies*, 2015, 33, (2), 160-174.
338. ZARATE C. : A randomized trial of an N-methyl-D-aspartate antagonist and neural correlation of rapid antidepressant response in treatment-resistant bipolar depression, *Biological Psychiatry*, 2011, 69, (9), 115S-115S.
339. ZINDBERG N.E. : Drug, set and setting : the basis for controlled intoxicant use, London, Yale University Press, 1984.

Addictions et thérapies psychédéliques :

1. ABRAMSON H.A. (Ed.) : The Use of LSD in Psychotherapy and Alcoholism, Bobbs-Merrill, Indianapolis, 1967, 407-426.
2. ABUZZAHAB F.S., ANDERSONB. J. : A review of LSD treatment in alcoholism. *International Pharmacopsychiatry*, 1971, 6 (4), 223–235. Doi : 10.1159/000468273
3. Alcoholics Anonymous : « Pass It On » The Story of Bill Wilson and How the A.A. Message Reached the World, *Alcoholics Anonymous World Services*, New York, pages 368-377, 1984.
4. ALPER K.R., LOTSOF H.S. : The Therapeutic Use of Peyote in the Native American Church, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 2)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, 2007, 43-66.
5. ANDERSON P. : Psychedelic Cuts Cravings, Consumption in Alcohol Use Disorder, Medscape, May 23 2019. www.medscape.com/viewarticle/913422
6. ARGENTO E., BRASCHEL M., WALSH Z., EUGENIA SOCIAS M., SHANNON K. : The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized woman, *Journal of Psychopharmacology*, 2018. Doi : 10.1177/0269881118798610
7. ARGENTO E., CAPLER R., THOMAS G., LUCAS P., TUPPER K.W. : Exploring ayahuasca-assisted therapy for addiction : A qualitative analysis of preliminary findings among an Indigenous community in Canada, *Drug and Alcohol Reviews*, 2019, 1-9. Doi : 10.1111/dar.12985
8. ARICIOGLU-KARTALA F., KAYIRB H., UZBAYB I.T. : Effects of harman and harmine on naloxone-precipitated withdrawal syndrome in morphine-dependent rats, *Life Sciences*, 2003, 73, 2363–2371.
9. BASTIAANS E. : Life after ibogaine : An exploratory study of the long-term effects of ibogaine treatment on drug addicts, 2004. www.ibogaine.desk.nl/ibogaine_udi_bastiaans.pdf
10. BELGERS M., LEENAARS M., HOMBERG J.R., RITSKES-HOITINGA M., SCHELLEKENS A.F., HOOIJMANS C.R. : Ibogaine and addiction in the animal model, a systematic review and meta-analysis, *Translational Psychiatry,* 2016, 6, e826.
11. BOGENSCHUTZ M.P., POMMY J.M. : Therapeutic mechanisms of classic hallucinogens in the treatment of addictions : from indirect evidence to testable hypotheses, *Drug Testing and Analysis*, 2012, 4, (7-8), 543–555.
12. BOGENSCHUTZ M.P., FORCEHIMES A.A., POMMY J.A., WILCOX C.E., BARBOSA P., STRASSMAN R.J. : Psilocybin-assisted treatment for alcohol dependence : A proof-of-concept study, *Journal of Psychopharmacology*, 2015, 29, (3), 289–299. Doi : 10.1177/0269881114565144
13. BOGENSCHUTZ M. P., JOHNSON M. W. : Classic hallucinogens in the treatment of addictions, *Progress in NeuroPsychopharmacology & Biological Psychiatry*, 2016, 64, 250–258. Doi : 10.1016/j.pnpbp.2015.03.002

14. BRAVO G., GORB C. : Psychedelic psychotherapy, in B. Scotton & A. Chinen (Eds.), *Textbook of transpersonal psychiatry and psychology* (pp. 335–343), New York, Basic Books, 1996.
15. BRIGHT S., WILLIAMS M., CALDICOTT D. : Should addiction researchers be interested in psychedelic science ? Editorial, *Drug and Alcohol Review*, 2017. Doi : 10.1111/dar.12544
16. BROWN T. K. : Ibogaine in the treatment of substance dependence, *Current Drug Abuse Reviews,* 2013, 6, 3–16. Doi : 10.2174/15672050113109990001
17. BROWN T. K., ALPER K. : Treatment of opioid use disorder with ibogaine : detoxification and drug use outcomes, *The American Journal of Drug and Alcohol Abuse*, 2017, 1-13. Doi : 10.1080/00952990.2017.1320802
18. CHWELOS N., BLEWETT D.C., SMITH C., HOFFER A. : Use of d-lysergic diethyl-amide in the treatment of alcoholism, *Quarterly Journal of Studies of Alcohol*, 1959, 20, 577–590. https://doi.org/10.1007/s00213-018-5010-9
19. CLOUTIER-GILL L., WOOD E., MILLAR T., FERRIS C., EUGENIA SOCIAS M. : Remission of severe opioid use disorder with ibogaine : a case report, *Journal of Psychoactive Drugs*, 2016, 48, 214-217.
20. DENYS A. : Importance d'une approche globale dans le traitement des addictions. Iboga et Ayahuasca, des perspectives intéressantes, in « *Chamanisme et thérapeutiques. Mythe ou réalité* », Jacques Fleurentin (ed), Metz, IEE-SFE, 10 juin 2004, Société française d'Ethnopharmacologie.
21. DENYS A. : Alliance des médecines occidentales et traditionnelles dans le traitement des addictions, Mémoire de Maitrise Sciences Sanitaires et Sociales, Mention Santé Publique, Faculté de Médecine / Université Henri Poincaré Nancy 1, 2004-2005.
22. DENYS A. : des plantes médicinales au service d'une action thérapeutique dans la prise en charge de l'addiction, *Ethnopharmacologia*, 2013, 50, 69-78.
23. DORSEN C., PALAMAR J., SHEDLIN M.G. : Ceremonial « Plant Medicine » use and its relationship to recreational drug use : an exploratory study, *Addiction Research and Theory,* 2018, 8 p. Doi : 10.1080/16066359.2018.1455187
24. Dos SANTOS R.G., OSORIO F. L., CRIPPA J.A.S., RIBA J., ZUARDI A. W., HALLAK J.E.C. : Antidepressive, anxiolytic, and anti-addictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD) : A systematic review of clinical trials published in the last 25 years, *Therapeutic Advances in Psychopharmacology*, 2016, 6, (3), 193–213. Doi : 10.1177/2045125316638008
25. DUPUIS D. : Le rite hallucinogène comme technique du Soi : une approche anthropologique de l'efficacité des psychédéliques dans le traitement des addictions, *Psychotropes*, 2020, 26, 1, 35-59.
26. DYCK E. : Hitting Highs at Rock Bottom : LSD Treatment for Alcoholism, 1950-1970, *Social History of Medicine*, 2006, 19, (2), 313-329.
27. EISCHENS P., ATHERTON L.W. : Psychedelic therapy as a complementary treatment approach for alcohol use disorders, *Journal of Psychedelic Studies,* 2018, 2, (1), pp. 36–44 Doi : 10.1556/2054.2018.005

28. GARCIA-ROMEU A.P., JOHNSON M.W., GRIFFITHS R.R. : Examining the psychological mechanisms of psilocybin- assisted smoking cessation treatment : A pilot study, *Drug and Alcohol Dependence*, 2014, 140, e66. Doi : 10.1016/j.drugalcdep.2014.02.200
29. GARCIA-ROMEU A., DAVIS A.K., EROWID F., EROWID E., GRIFFITHS R.R., JOHNSON M.W. : Cessation and reduction in alcohol consumption and misuse after psychedelic use, *Journal of Psychopharmacology*, 2019, 1-14. Doi : 10.1177/0269881119845793
30. GARCIA-ROMEU A., DAVIS A.K., EROWID E., EROWID F., GRIFFITHS R.R., JOHNSON M.W. : Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic psychedelic Use : An Online Survey, *Frontiers in Psychiatry*, 2020, Vol 10, Article 955. Doi : 10.3389/fpsyt.2019.00955
31. GLUE P., CAPE G., TUNNICLIFF D., LOCKHART M., LAM F., HUNG N., HUNG C.T., HARLAND S., DEVANE J., CROCKETT R.S., HOWES J., DARPO B., ZHOU M., WIS H., FRIEDHOFF L. : Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients, *Clinical Pharmacology in Drug Development,* 2016, 5, (6), 460–468. Doi : 10.1002/cpdd.254
32. GRIFFITHS R., GROB C. : Hallucinogens as Medicine, *Scientific American*, 2010, 76-79.
33. HALPERN J. H. : The use of hallucinogens in the treatment of addiction, *Addiction Research,* 1996, 4, (2), 177-189.
34. HALPERN J.H. : Hallucinogens in the Treatment of Alcoholism and Other Addictions, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 2)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, 2007, 1-14.
35. HOFFER A. : Treatment of Alcoholism with Psychedelic Therapy, in « *Psychedelics* », Aaronson B.S. and Osmond H. ed., 1970, 357-365.
36. JEROME L., SCHUSTER S., YAZAR-KLOSINSKI B. : Can MDMA Play a Role in the Treatment of Substance Abuse, *Current Drug Abuse Reviews*, 2013, 6, 54-62.
37. JOHNSON M.W., GARCIA-ROMEU A., COSIMANO M.P., GRIFFITHS R.R. : Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction, *Journal of Psychopharmacology*, 2014, 28, (11), 983– 992. Doi : 10.1177/0269881114548296
38. JOHNSON M.W., GARCIA-ROMEU A., GRIFFITHS R.R. : Long-term follow-up of psilocybin-facilitated smoking cessation, *American Journal of Drug Alcohol Abuse*, 2017, 43, 1, 55– 60. Doi : 10.3109/00952990.2016.1170135
39. JOHNSON M.W., GARCIA-ROMEU A., JOHNSON, P.S., GRIFFITHS R.R. : An online survey of tobacco smoking cessation associated with naturalistic psychedelic use, *Journal of Psychopharmacology*, 2017, 31, (7), 841–850.
40. JOHNSON M.W., GRIFFITHS R.R. : Potential Therapeutic Effects of Psilocybin, *Neurotherapeutics*, 2017, 14, 734-740. Doi : 10.1007/s13311-017-0542-y
41. JOHNSON M.W., GRIFFITHS R.R., HENDRICKS P.S., HENNINGFIELD J.E. : The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act, *Neuropharmacology*, 2018, 142, 143-166. Doi : 10.1016/j.neuropharm.2018.05.012

42. JOHNSON M.W., HENDRICKS P.S., BARRETT F.S., GRIFFITHS R.R. : Classic psychedelics : An integrative review of epidemiology, therapeutics, mystical experience, and brain network function, *Pharmacology & Therapeutics,* 2019. https://doi.org/10.1016/j.pharmthera.2018.11.010
43. KARILA L., REYNAUD M., AUBIN H. J., ROLLAND B., GUARDIA D., COTTENCIN O., BENYAMINA A. : Pharmacological treatments for cocaine dependence: Is there something new ?, *Current Pharmaceutical Design*, 2011, 17, 1359–1368. Doi : 10.2174/138161211796150873
44. KREBS T.S., JOHANSEN P.-Ø. : Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials, *Journal of Psychopharmacology*, 2012, 26, (7), 994–1002. Doi : 10.1177/0269881112439253
45. KRUPITSKY E.M., GRINENKO A.Y., BERKALIEV T.N. et al. : The combination of psychedelic and aversive approaches in alcoholism treatment : The affective contra-attribution method, *Alcoholism Treatment Quarterly*, 1992, 9, 99-105.
46. KRUPITSKY E. : Underlying psychological mechanisms of ketamine psychedelic therapy (KPT) in the treatment of alcohol dependency : preliminary report, *Bulletin of the MAPS*, 1995, 6, (1), 2 p.
47. KRUPITSKY E. : Ketamine study at Yale : an update, *Bulletin of the MAPS*, 1996, 7, (1), 1.
48. KRUPITSKY E.D., GRINENKO A.Y. : Ketamine psychedelic therapy : a review of the results of ten years of research, *Journal of Psychoactive Drugs*, 1997, 8, (2), 165-182.
49. KRUPITSKY E.M., GRINENKO A.Y. : Ketamine psychedelic therapy (KPT) : a review of the results of ten years of research, *Journal of Psychoactive Drugs*, 1997, 29, (2), 165-183.
50. KRUPITSKY E.D., GRINENKO A.Y. : Ten years study of ketamine psychedelic therapy of alcohol dependence, *The Heffter Review of Psychedelic Research*, 1998, 8, 1, 56-61.
51. KRUPITSKY E.D. BURAKOV A., GRINENKOA. Y. : Correlation Between Ketamine Psychotherapy (KPT) Induced Psychological Changes and Alcoholism Treatment Outcome, *Bulletin of the MAPS*, 1999, 9, (1), 39-40.
52. KRUPITSKY E.D. BURAKOVA., ROMANOVA, T., VOSTRIKOV V., GRINENKO A.Y. : The syndrome of anhedonia in recently detoxified heroin addicts assessment and treatment, *Bulletin of the MAPS*, 1999, 9, (1), 40-41.
53. KRUPITSKY E.D. : Ketamine psychedelic therapy : two reports, *Bulletin of the MAPS,* 1999, 9, (1), 39-41.
54. KRUPITSKY E.M., BURAKOV A., ROMANOVA T. : Ketamine psychotherapy for heroin addiction : immediate effects and two-year follow-up, *Journal of Substance Abuse Treatment*, 2002, 23, 273-283.
55. KRUPITSKY E.M., BURAKOV A., DUNAEVSKYI. V. et al. : Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence, *Journal of Psychoactive Drugs*, 2007, 39, (1), 13-19.
56. KRUPITSKY E., KOLP E. : Ketamine Psychedelic Psychotherapy, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 2)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, London, 2007, 67-85.

57. KURLAND A.A., UNGER S. : The psychedelic procedure in the treatment of the alcoholic patient, in Abramson H.A. (ed) "*The Use of LSD in Psychotherapy and Alcoholism*", Bobbs-Merrill Company Inc., Indianapolis, 1967.
58. KURLAND A.A., UNGER S., SHAFFER J.W., SAVAGE C. : Psychedelic therapy utilizing LSD in the treatment of the alcoholic patient: a preliminary report, *American Journal of Psychiatry*, 1967, 123, (10), 1202–1209.
59. KURLAND A., SAVAGE C., PAHNKE W.N., GROF S., OLSSON J.E. : LSD in the treatment of Alcoholics, *Pharmakopsychiatrie und Neuro-Psychopharmakologie*, 1971, 4, (2), 83-94.
60. KURLAND A.A. : American College on Neuropsychopharmacology (ACNP) interview by Leo E. Hollister, 1997. https://www.acnp.org/programs/history.aspx#
61. KVAM T.-M., STEWART L.H., ANDREASSEN O.A. : Psychedelic drugs in the treatment of anxiety, depression and addiction, *Tidsskriftet, Den Norske Legeforening,* 2018. Doi : 10.4045/tidsskr.17.1110
62. LABATE B.C., CAVNAR C. (Eds.) : The Therapeutic Use of Ayahuasca, Springer-Verlag, Berlin, Heidelberg, 2014. Doi : 10.1007/978-3-642-40426-9
63. LIESTER M.B. : A Review of Lysergic Acid Diethylamide (LSD) in the Treatment of Addictions : Historical Perspectives and Future Prospects, *Current Drug Abuse Reviews*, 2014, 7, 146-156.
64. LOIZAGA-VELDE, A., VERRES R. : Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence: Qualitative results, *Journal of Psychoactive Drugs*, 2014, 46, (1), 63-72.
65. LOTSOF H.S., ALEXANDER N.E. : Case studies of ibogaine treatment : implications for patient management strategies, *The Alkaloids. Chemistry and Biology*, 2001, 56, 293–313.
66. MABIT J. : Chamanisme amazonien et toxicomanie - Initiation et contre-initiation, Agora , 1993, 27/28, 139-146.
67. MABIT J. : Le savoir médical traditionnel et la toxicomanie, Centre Tarapoto, Pérou, 1994.
68. MABIT J. : Ayahuasca in the Treatment of Addictions, in "*Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 2)*", M.J. Winkelman & T.B. Roberts Eds., Westport, CT, Praeger/Greenwood Publishers, London, 2007, 87-106.
69. MANGINI M. : Treatment of alcoholism using psychedelic drugs: a review of the program of research, *Journal of Psychoactive Drugs*, 1998, 30, (4), 381-418. Doi : 10.1080/02791072.1998.10399714
70. McLEAN J.R., MacDONALD D.C., OGDEN F., WILBY E. : LSD-25 and mescaline as therapeutic adjuvants, in Abramson H.A. (Ed.) : « *Use of LSD in Psychotherapy and Alcoholism* », Bobbs-Merrill, Indianapolis, 1967, 407-426.
71. MIRALLES A., ESTEBAN S., SASTRE-COLL A., MORANTA D., ASENSIO V.J., GARCIA-SEVILLA J.A. : High-affinity binding of β-carbolines to imidazoline I2B receptors and MAO-A in rat tissues : Norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain, *European Journal of Pharmacology*, 2005, 518, 234 – 242.

72. NOORANI T., GARCIA-ROMEU A., SWIFT T.C., GRIFFITHS R.R., JOHNSON M.W. : Psychedelic therapy for smoking cessation : Qualitative analysis of participant accounts, *Journal of Psychopharmacology*, 2018, 1-14.
Doi : 10.1177/0269881118780612
73. NUNES A.A., DOS SANTOS R.G., OSORIO F.L., SANCHES R.F., CRIPPA J.A.S., HALLAK J.E. : Effects of ayahuasca and its alkaloids on drug dependence : A systematic literature review of quantitative studies in animals and humans, *Journal of Psychoactive Drugs*, 2016, 48, (3), 195-205.
74. O'REILLY P., FUNK A. : LSD in chronic alcoholism, *Canadian Psychiatric Association Journal,* 1964, 9, 258–261.
Doi : 10.1177/070674376400900311
75. OSMOND H., CHEEK F., ALBAHARY R., SARRET M. : Some Problems in the use of LSD 25 in the Treatment of alcoholism, in Abramson H.A. (Ed.) : « *Use of LSD in Psychotherapy and Alcoholism* », Bobbs-Merrill, Indianapolis, 1967, 434-453.
76. POLITI M., FRISO F., MABIT J. : Plant based assisted therapy for the treatment of substance use disorders – part 1. The case of Takiwasi Center and other similar experiences, *Revista Cultura y Droga*, 2018, 23, (26), 99-126.
Doi : 10.17151/culdr.2018.23.26.7
77. PRICKETT J.I., LIESTER M.B. : Hypotheses Regarding Ayahuasca's Potential Mechanisms of Action in the Treatment of Addiction, Chapter 7, in « *The Therapeutic Use of Ayahuasca* », B.C. Labate and C. Cavnar, Springer Berlin Heidelberg, 2014, 111-132.
78. RIBEIRO BARBOSA P.C., TOFOLI L.F., BOGENSCHUTZ M.P., HOY R., BERRO L.F., MARINHO E.A.V., ARECO K.N., WINKELMAN M.J. : Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca, *Frontiers in Psychiatry*, 2018, Vol 9, Article 136, 1-11.
Doi : 10.3389/fpsyt.2018.00136
79. SAVAGE C., McCABE O.L. : Residential Psychedelic (LSD) Therapy for the Narcotic Addict, *Archives of General Psychiatry,* 1973, 28, 808-814.
80. SCHENBERGE E.E., de CASTRO COMIS, M. A., CHAVES B.R., da SILVEIRA D.X. : Treating drug dependence with the aid of ibogaine: A retrospective study, *Journal of Psychopharmacology (*Oxford, England), 2014, 28, (11), 993–1000.
Doi : 10.1177/0269881114552713
81. SHULGIN Al., SHULGIN An. : PIKHAL : a chemical love story, Berkeley, Transform Press, 1991/1995.
82. SILVA O., SIMOES M. : Ayahuasca as a mind enhancer – Its knowledge and potential, 12° Simposio da Fundaçao Bial, "*Aquém e Além do Cérebro. Behind and Beyond the Brain"*, 2018, 143-152.
83. SISCO B. : Interrupting drug dependency with ibogaine : a summary of four case histories, *Multidisciplinary Association on Psychedelic Studies (MAPS), Newsletter*, 1993, 4, 15-24.
84. SMITH CM. : A new adjunct to the treatment of alcoholism: the hallucinogenic drugs, *Quarterly Journal of Studies on Alcohol*, 1958, 19, 406–417.
85. SOSKIN R.A. : The Use of LSD in Time-Limited Psychotherapy, *Journal of Nervous and Mental Disease*, 1973, 157, (6), 410-419.
86. TALIN P., SANABRIA E. : Ayahuasca's entwined efficacy : An ethnographic study of ritual healing from "addiction", *International Journal of Drug Policy,* 2017, 44, 23-30.
Doi : 10.1016/j.drugpo.2017.02.017

87. THOMAS G., LUCAS P., CAPLER R.N., TUPPER K.W., MARTIN G. : Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada, *Current Drug Abuse Review,* 2013, 6 (1). http://www.maps.org/research-archive/ayahuasca/Thomas_et_al_CDAR.pdf
88. VARIAS A., van ROESSEL P., PARSIANI M., FILIPPOU-FRYE M., NEYLAN T.C., NAGELE P., YESAVAGE J., CLARK J.D., RODRIGUEZ C. : Does Nitrous Oxyde Help Veterans with Posttraumatic Stress Disorder ?, *Journal of Clinical Psychiatry*, 2020, 81, 4, e1-e2.
89. VERROUST V., LEBEAU LEIBOVICI B. : Soignera-t-on un jour grâce au LSD et aux champignons hallucinogènes ? The Conversation, 8 octobre 2020. https://theconversation.com/soignera-t-on-un-jour-grace-au-lsd-et-aux-champignons-hallucinogenes-127760
90. WEBB H.S. : The Use of Peyote as Treatment for Alcoholism within the NAC Community : Reflections on a Study; An Interview with John Halpern, MD, *Anthropology of Consciousness*, 2011, 22, (2), 234-244.
91. WINKELMAN M.J., ROBERTS T.B. : Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 1 & 2), Westport, CT, Praeger/Greenwood Publishers, 2007.
92. WINKELMAN M.J. : Shamanism : A biopsychosocial paradigm of consciousness and healing (2nd ed.), Santa Barbara, CA: ABC-CLIO, 2010.
93. WINKELMAN M.J. : Psychedelics as medicines for substance abuse rehabilitation : Evaluating treatments with LSD, peyote, ibogaine and ayahuasca, *Current Drug Abuse Reviews*, 2014, 7, 101-116.
94. YASGHUR B.S. : Ketamine Promising in Cocaine Addiction, *Medscape Medical News*, 2019 https://www.medscape.com/viewarticle/915260_print
95. ZINBERG N. : Drugs : Set and Setting, New Haven, Yale University Press, 1984.